{"id":"cozzar-tablet","safety":{"commonSideEffects":[{"rate":"7-10","effect":"Dizziness"},{"rate":"3-5","effect":"Fatigue"},{"rate":"2-4","effect":"Hyperkalemia"},{"rate":"1-2","effect":"Cough"},{"rate":"5-7","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL635","moleculeType":"Small molecule","molecularWeight":"358.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Losartan is an angiotensin II receptor antagonist (ARB) that selectively blocks AT1 receptors on vascular smooth muscle and other tissues. By preventing angiotensin II from binding to these receptors, it causes vasodilation and reduces aldosterone secretion, leading to decreased blood pressure and reduced sodium retention. This mechanism makes it effective for hypertension management and renal protection in diabetic patients.","oneSentence":"Cozzar (losartan) blocks angiotensin II receptors to relax blood vessels and lower blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:31:18.662Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Diabetic nephropathy in patients with type 2 diabetes"},{"name":"Heart failure"}]},"trialDetails":[{"nctId":"NCT05090449","phase":"PHASE1","title":"Non-interaction Study of Chlorthalidone and Losartan in Fixed Combination, in Healthy Subjects, Under Fasting Conditions","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2019-05-01","conditions":"Healthy","enrollment":36},{"nctId":"NCT01766505","phase":"PHASE4","title":"The Study to Evaluate Efficacy and Safety of Candesartan vs Losartan in Hypertension With Heart Failure (HONOR)","status":"TERMINATED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2012-06","conditions":"Hypertension","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35895,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cozzar tablet","genericName":"Cozzar tablet","companyName":"Chong Kun Dang Pharmaceutical","companyId":"chong-kun-dang-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cozzar (losartan) blocks angiotensin II receptors to relax blood vessels and lower blood pressure. Used for Hypertension, Diabetic nephropathy in patients with type 2 diabetes, Heart failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}